Kyverna Therapeutics (KYTX) EBIT (2023 - 2026)
Kyverna Therapeutics' (KYTX) quarterly EBIT came in at -$41.4 million in Q1 2026, up 12.74% YoY from -$36.7 million in Q1 2025, and down 5.31% on a QoQ basis from -$39.3 million in Q4 2025.
Kyverna Therapeutics (KYTX) EBIT (2023 - 2026) Analysis & Trends
Kyverna Therapeutics (KYTX) has 4 years of EBIT data on file, last reported at -$41.4 million in Q1 2026.
- Quarterly EBIT rose 12.74% year-over-year to -$41.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$163.8 million (down 1.95% YoY) and the FY2025 annual result came in at -$169.8 million, down 19.09% from the prior year.
- EBIT slipped to -$41.4 million in Q1 2026, from -$39.3 million in the prior quarter.
- In the past five years, EBIT ranged from a high of -$11.4 million in Q1 2023 to a low of -$47.4 million in Q1 2025.
- A 4-year average of -$32.0 million and a median of -$38.7 million in 2025 frame the typical range for EBIT.
- Annual changes were most pronounced in 2024 — EBIT slumped 156.51% — and 2026, when it grew 12.74%.
- Tracing KYTX's EBIT over 4 years: stood at -$21.4 million in 2023, then tumbled by 91.99% to -$41.0 million in 2024, then climbed by 4.29% to -$39.3 million in 2025, then dropped by 5.31% to -$41.4 million in 2026.
- The last three EBIT figures came in at -$41.4 million (Q1 2026), -$39.3 million (Q4 2025), and -$38.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Kyverna Therapeutics | 505.26 Mn | 505.26 Mn | - | -39.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -39.56 Mn |
| Mar 31, 2026 | -41.37 Mn |
| Dec 31, 2025 | -39.28 Mn |
| Sep 30, 2025 | -38.73 Mn |
| Jun 30, 2025 | -44.41 Mn |
| Mar 31, 2025 | -47.41 Mn |
| Dec 31, 2024 | -41.04 Mn |
| Sep 30, 2024 | -38.77 Mn |
| Jun 30, 2024 | -33.44 Mn |
| Mar 31, 2024 | -29.36 Mn |
| Dec 31, 2023 | -21.38 Mn |
| Sep 30, 2023 | -16.28 Mn |
| Jun 30, 2023 | -13.30 Mn |
| Mar 31, 2023 | -11.45 Mn |